Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Strides Pharma Science
STAR
Strides Pharma Science
US Market Dependency Will Strain Margins Yet Yield Opportunity
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
03 Aug 25
Updated
12 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹937.00
4.5% undervalued
intrinsic discount
12 Aug
₹895.15
Loading
1Y
-27.0%
7D
12.1%
Author's Valuation
₹937.0
4.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹937.0
4.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-4b
67b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹66.8b
Earnings ₹9.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.70%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹9.21b
Earnings '28
x
13.41x
PE Ratio '28
=
₹123.49b
Market Cap '28
₹123.49b
Market Cap '28
/
92.92m
No. shares '28
=
₹1.33k
Share Price '28
₹1.33k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹927.73
Fair Value '25
